Details of the Drug Combination

General Information of Drug Combination (ID: DC6QUFG)

Drug Combination Name

Hepzato Pentostatin

Indication

Disease Entry	Status	REF
Cutaneous melanoma	Investigative	[1]

Component Drugs

Hepzato DM2AZPP

Pentostatin DM0HXDS

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: SK-MEL-28

Zero Interaction Potency (ZIP) Score: 0.45

Bliss Independence Score: 4.52

Loewe Additivity Score: 1.21

LHighest Single Agent (HSA) Score: 1.71

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

Indication(s) of Pentostatin

Disease Entry	ICD 11	Status	REF
Acute graft versus host disease	4B24.0	Approved	[3]
Hairy cell leukaemia	2A82.2	Approved	[4]
Leukemia	N.A.	Approved	[3]

Pentostatin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Inhibitor	[5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DCQADI6	U251	Investigative	[6]
Clear cell renal cell carcinoma	DCMB4TA	786-0	Investigative	[6]
Glioma	DCAVCMM	SF-539	Investigative	[6]
Adenocarcinoma	DC8JS4N	HCT-15	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3	Pentostatin FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4805).
5	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
6	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.